Literature DB >> 33456710

Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer.

Krastan B Blagoev1,2, Roumen Iordanov3, Mengxi Zhou4,5, Tito Fojo4,5, Susan E Bates4,5.   

Abstract

Most metastatic cancers develop drug resistance during treatment and continue to grow, driven by a subpopulation of cancer cells unresponsive to the therapy being administered. There is evidence that metastases are formed by phenotypically plastic cancer cells with stem-cell like properties. Currently the population structure and growth dynamics of the resulting metastatic tumors is unknown. Here, using scaling analysis of clinical data of tumor burden in patients with metastatic prostate cancer, we show that the drug resistant, metastasis-causing cells (MCC) are capable of producing drug resistant, exponentially growing tumors, responsible for tumor growth as a patient receives different treatments. Copyright:
© 2021 Blagoev et al.

Entities:  

Keywords:  cancer stem cells; drug resistance; exponential growth; metastatic prostate cancer; tumor kinetics

Year:  2021        PMID： 33456710      PMCID： PMC7800777          DOI： 10.18632/oncotarget.27855

Source DB:  PubMed          Journal:  Oncotarget        ISSN： 1949-2553


  27 in total

1.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

2.  Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.

Authors:  K Fizazi; J S De Bono; A Flechon; A Heidenreich; E Voog; N B Davis; Ming Qi; R Bandekar; J T Vermeulen; M Cornfeld; G R Hudes
Journal:  Eur J Cancer       Date:  2011-11-28       Impact factor: 9.162

3.  Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Authors:  Ian F Tannock; Karim Fizazi; Sergey Ivanov; Camilla Thellenberg Karlsson; Aude Fléchon; Iwona Skoneczna; Francisco Orlandi; Gwenaelle Gravis; Vsevolod Matveev; Sevil Bavbek; Thierry Gil; Luciano Viana; Osvaldo Arén; Oleg Karyakin; Tony Elliott; Alison Birtle; Emmanuelle Magherini; Laurence Hatteville; Daniel Petrylak; Bertrand Tombal; Mark Rosenthal
Journal:  Lancet Oncol       Date:  2013-06-04       Impact factor: 41.316

4.  Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.

Authors:  Fred Saad; Karim Fizazi; Viorel Jinga; Eleni Efstathiou; Peter C Fong; Lowell L Hart; Robert Jones; Raymond McDermott; Manfred Wirth; Kazuhiro Suzuki; David B MacLean; Ling Wang; Hideyuki Akaza; Joel Nelson; Howard I Scher; Robert Dreicer; Iain J Webb; Ronald de Wit
Journal:  Lancet Oncol       Date:  2015-02-18       Impact factor: 41.316

5.  Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

Authors:  M Dror Michaelson; Stephane Oudard; Yen-Chuan Ou; Lisa Sengeløv; Fred Saad; Nadine Houede; Peter Ostler; Arnulf Stenzl; Gedske Daugaard; Robert Jones; Fredrik Laestadius; Anders Ullèn; Amit Bahl; Daniel Castellano; Juergen Gschwend; Tristan Maurina; Edna Chow Maneval; Shaw-Ling Wang; Maria Jose Lechuga; Jolanda Paolini; Isan Chen
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

6.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

7.  Organoid cultures derived from patients with advanced prostate cancer.

Authors:  Dong Gao; Ian Vela; Andrea Sboner; Phillip J Iaquinta; Wouter R Karthaus; Anuradha Gopalan; Catherine Dowling; Jackline N Wanjala; Eva A Undvall; Vivek K Arora; John Wongvipat; Myriam Kossai; Sinan Ramazanoglu; Luendreo P Barboza; Wei Di; Zhen Cao; Qi Fan Zhang; Inna Sirota; Leili Ran; Theresa Y MacDonald; Himisha Beltran; Juan-Miguel Mosquera; Karim A Touijer; Peter T Scardino; Vincent P Laudone; Kristen R Curtis; Dana E Rathkopf; Michael J Morris; Daniel C Danila; Susan F Slovin; Stephen B Solomon; James A Eastham; Ping Chi; Brett Carver; Mark A Rubin; Howard I Scher; Hans Clevers; Charles L Sawyers; Yu Chen
Journal:  Cell       Date:  2014-09-04       Impact factor: 41.582

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

Authors:  Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

9.  Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas.

Authors:  Arnout G Schepers; Hugo J Snippert; Daniel E Stange; Maaike van den Born; Johan H van Es; Marc van de Wetering; Hans Clevers
Journal:  Science       Date:  2012-08-01       Impact factor: 47.728

10.  Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.

Authors:  Mauricio Burotto; Julia Wilkerson; Wilfred Stein; Robert Motzer; Susan Bates; Tito Fojo
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240
View more
  1 in total

Review 1.  Understanding and targeting prostate cancer cell heterogeneity and plasticity.

Authors:  Dean G Tang
Journal:  Semin Cancer Biol       Date:  2021-11-26       Impact factor: 17.012
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.